Impact of Covid–19 coronavirus on private fundraisings – key legal considerations for investors and issuers
Headlines in this article
Related news and insights
Blog Post: 20 June 2022
Blog Post: 05 January 2022
Publications: 03 December 2021
Blog Post: 12 October 2021
Investors are heightened to the potential risks and liabilities associated with new investments, with some shifting focus to their existing portfolios and ensuring those businesses are sufficiently capitalised to ride out the inevitable global downturn.
There will undoubtedly be regional differences, but the sector is almost certainly going to slow in terms of overall activity in the short to medium term. However, high cash-burn companies will still need to come to market in the coming months and there remains record amounts of cash available for deployment.
As with any significant disruption, new opportunities will arise, particularly in sectors such as technology and life sciences. We are seeing both Investors and Issuers having to adjust their expectations as to the timing and contractual terms required to successfully close fundraising processes, and Issuers are looking increasingly at alternative financing options to running a full equity round.
We have summarized below certain of the key legal and market issues which both Investors and Issuers should consider in light of Covid-19.